Cargando…
Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288765/ http://dx.doi.org/10.1186/2051-1426-2-S3-P88 |
| _version_ | 1782352020347289600 |
|---|---|
| author | Kaufman, Howard L Aung, Sandra Morse, Michael Wong, Michael Lowder, James Daniels, Gregory McDermott, David |
| author_facet | Kaufman, Howard L Aung, Sandra Morse, Michael Wong, Michael Lowder, James Daniels, Gregory McDermott, David |
| author_sort | Kaufman, Howard L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288765 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887652015-01-15 Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 Kaufman, Howard L Aung, Sandra Morse, Michael Wong, Michael Lowder, James Daniels, Gregory McDermott, David J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288765/ http://dx.doi.org/10.1186/2051-1426-2-S3-P88 Text en Copyright © 2014 Kaufman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Kaufman, Howard L Aung, Sandra Morse, Michael Wong, Michael Lowder, James Daniels, Gregory McDermott, David Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 |
| title | Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 |
| title_full | Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 |
| title_fullStr | Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 |
| title_full_unstemmed | Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 |
| title_short | Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 |
| title_sort | stable disease after high dose interleukin-2 (hd il-2) immunotherapy: observations on long term survival and clinical benefit of additional hd il-2 |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288765/ http://dx.doi.org/10.1186/2051-1426-2-S3-P88 |
| work_keys_str_mv | AT kaufmanhowardl stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 AT aungsandra stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 AT morsemichael stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 AT wongmichael stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 AT lowderjames stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 AT danielsgregory stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 AT mcdermottdavid stablediseaseafterhighdoseinterleukin2hdil2immunotherapyobservationsonlongtermsurvivalandclinicalbenefitofadditionalhdil2 |